IB
IBRX
-4.4%🟢 Fundamentally supportedImmunityBio, Inc. Common Stock · Healthcare
$9.55Vol 12.34M · 1.0× normalMkt cap −$0.47Blive · 2026-10-16 ET
What happened
Move
-4.4%
Price
$9.55
Volume
12.34M
1.0× normal
Market cap
$10.13B
−$0.47B today
Why it moved
Legal / regulatorymedium confidence
- FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer — finnhub-news
- IBRX Stock Eyes Weekly Slump Despite Anktiva FDA Win — Retail Stays Cautious Ahead Of Founder’s Trial Talk — finnhub-news
Possible catalyst: legal / regulatory, 3.4pp below its sector.
Verdict — was the move justified?
🟢 Fundamentally supported
Legal / regulatory — direction and rough magnitude are consistent with the identified fundamental catalyst.
How unusual is this move
σ score
1.2σ
vs own 20d volatility
Percentile
61th
of 1269 daily moves
Avg daily move
±4.8%
own 5y average
vs sector
-3.4%
beyond sector median
What happened after similar moves
238 similar down moves in IBRX’s 5-year history:
After 5 days
-1.0%
45% higher
After 20 days
-0.4%
49% higher
Median of same-direction moves within ±35% magnitude band. Past patterns don’t predict outcomes — context, not signal.
Fundamental context
V 20G 25P 0H 28Q 10
Insider activity (90d): net selling $1.12M
Full fundamental analysis on PreMarketPrice
Pillar scores, financial statements, valuation history, news & more for IBRX